Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

aTYR PHARMA INC Director's Dealing 2022

Jan 10, 2022

34337_dirs_2022-01-10_5ed45b4b-e874-4230-9212-8c81280e854b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: aTYR PHARMA INC (LIFE)
CIK: 0001339970
Period of Report: 2022-01-07

Reporting Person: Shukla Sanjay (Director, President and CEO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-01-07 Common Stock P 5000 $6.7613 Acquired 25798 Direct